Bank of America’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-836,641
| Closed | -$50.1M | – | 7572 |
|
|
2019
Q4 | $50.1M | Buy |
836,641
+797,510
| +2,038% | +$29.9M | 0.01% | 1178 |
|
|
2019
Q3 | $1.1M | Sell |
39,131
-46,051
| -54% | -$1.57M | ﹤0.01% | 4491 |
|
|
2019
Q2 | $3.23M | Sell |
85,182
-12,626
| -13% | -$485K | ﹤0.01% | 3632 |
|
|
2019
Q1 | $3.82M | Buy |
97,808
+62,882
| +180% | +$1.8M | ﹤0.01% | 3417 |
|
|
2018
Q4 | $744K | Sell |
34,926
-12,629
| -27% | -$326K | ﹤0.01% | 4637 |
|
|
2018
Q3 | $1.88M | Sell |
47,555
-2,592
| -5% | -$96.6K | ﹤0.01% | 4025 |
|
|
2018
Q2 | $1.92M | Buy |
50,147
+5,356
| +12% | +$198K | ﹤0.01% | 4007 |
|
|
2018
Q1 | $1.35M | Buy |
44,791
+5,607
| +14% | +$190K | ﹤0.01% | 4175 |
|
|
2017
Q4 | $1.22M | Buy |
39,184
+7,712
| +25% | +$212K | ﹤0.01% | 4348 |
|
|
2017
Q3 | $882K | Buy |
31,472
+2,976
| +10% | +$64.6K | ﹤0.01% | 4599 |
|
|
2017
Q2 | $546K | Buy |
28,496
+5,097
| +22% | +$81.4K | ﹤0.01% | 4840 |
|
|
2017
Q1 | $399K | Buy |
23,399
+4,310
| +23% | +$69.7K | ﹤0.01% | 5001 |
|
|
2016
Q4 | $348K | Sell |
19,089
-1,017
| -5% | -$17.6K | ﹤0.01% | 5039 |
|
|
2016
Q3 | $358K | Buy |
+20,106
| New | +$305K | ﹤0.01% | 4845 |
|
Bank of America's BOLD Position: Q1 2020 in Review
Bank of America sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 836,641 shares — an estimated $50.1M sold.
Bank of America first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $50.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Bank of America reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Bank of America sold 836,641 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $50.1M.
- Bank of America first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Bank of America's Audentes Therapeutics, Inc position peaked at $50.1M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Bank of America's 13F filing for Q1 2020, filed 15 May 2020.